ABVC BioPharma's gross profit for the
three
months ended in Mar. 2026 was $0.00 Mil. ABVC BioPharma's gross profit for the trailing twelve months (TTM) ended in Mar. 2026 was $0.00 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. ABVC BioPharma's gross profit for the
three
months ended in Mar. 2026 was $0.00 Mil. ABVC BioPharma's Revenue for the
three
months ended in Mar. 2026 was $0.00 Mil. Therefore, ABVC BioPharma's Gross Margin % for the quarter that ended in Mar. 2026 was N/A%.
ABVC BioPharma had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
During the past 13 years, the highestGross Margin % of ABVC BioPharma was 99.80%. The lowest was -98.68%. And the median was 96.61%.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
ABVC BioPharma had a gross margin of N/A% for the quarter that ended in Mar. 2026 => No sustainable competitive advantage
ABVC BioPharma Gross Profit Related Terms
ABVC BioPharma Gross Profit Historical Data
* Premium members only.
The historical data trend for ABVC BioPharma's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, ABVC BioPharma's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABVC BioPharma Gross Profit vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, ABVC BioPharma's Gross Profit distribution charts can be found below:
* The bar in red indicates where ABVC BioPharma's Gross Profit falls into.
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
(Note that if there's no value for Cost of Goods Sold, then Gross Margin % is not calculated.)
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
ABVC BioPharma (ABVC) has a Gross Profit of $0.00 Mil as of Mar. 2026. Gross Profit equals net sales less total cost of goods sold. View historical data on ABVC BioPharma and its competitors.
Is ABVC BioPharma's Gross Profit too high?
ABVC BioPharma's current Gross Profit is $0.00 Mil. Overall, ABVC BioPharma has a GF Score™ of 17/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ABVC BioPharma's Gross Profit compare to GRCE and ELOX?
ABVC BioPharma's Gross Profit of $0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Profit for a Biotechnology company?
A good Gross Profit depends on the Biotechnology industry context. However, Gross Profit should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Profit mean?
A high Gross Profit can signal that a stock is expensive relative to its fundamentals. Gross Profit equals net sales less total cost of goods sold. View historical data on ABVC BioPharma and its competitors. ABVC BioPharma's current Gross Profit is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABVC BioPharma stock overvalued right now?
Based on GuruFocus' analysis, ABVC BioPharma (ABVC) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.87, compared to a current price of $1.51 — trading 73.6% above its estimated fair value. The current Gross Profit is $0.00 Mil. ABVC BioPharma's overall GF Score™ is 17/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Profit calculated?
Gross Profit is calculated from a company's financial statements. For ABVC BioPharma (ABVC), the current Gross Profit is $0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABVC BioPharma (ABVC) Overvalued in 2026?
Based on GuruFocus' analysis, ABVC BioPharma stock appears to be overvalued.
The current stock price of $1.51 is trading 73.6% above its estimated GF Value™ of $0.87.
GuruFocus considers ABVC BioPharma to be Significantly Overvalued.
Key valuation signals for ABVC:
Gross Profit: $0.00 Mil
GF Value™: $0.87 vs. price of $1.51 (73.6% above fair value)
No single metric tells the full story. See the ABVC stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABVC BioPharma Inc is a clinical stage biopharmaceutical company focused on development of new drugs and medical devices, all of which are derived from plants. It currently has six drugs and three medical devices in development. The firm specializes in botanically based solutions that deliver high efficacy with low toxicity for improved health outcomes. Its products include: Vitargus - ABV-1701, ABV-2001, ABV-2002, MDD ABV-1504, ADHD ABV-1505, ADHD ABV-1601, ABV-1501, ABV-1702, and ABV-1703.
17GF Score
Get the complete analysis for ABVC
Gross Profit is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ABVC has been successfully added to your 
